Photo taken from Photo from Guilherme Nader Marta/X
Jun 14, 2024, 03:24
Guilherme Nader Marta: Our Review On the PI3K/Akt-targeted Agents
Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared on X:
“PI3K/Akt-targeted agents entered clinical practice & may soon bring precision oncology to 1st line of Tx for ER+ breast cancer
Out in Critical Reviews in Oncology Hematology (CROH) our review on the activity, biomarkers & toxicities w/ these agents & next steps in the field”
Read further.
Source: Guilherme Nader Marta/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 23, 2024, 03:08
Oct 23, 2024, 02:59
Oct 23, 2024, 02:53
Oct 23, 2024, 02:46
Oct 23, 2024, 00:05
Oct 22, 2024, 23:59
Oct 22, 2024, 23:53